
DocGo (DCGO) Stock Forecast & Price Target
DocGo (DCGO) Analyst Ratings
Bulls say
DocGo is expected to experience strong growth in its Medical Mobility revenue due to the expansion into new markets and its integration of a logistics platform and lower-cost staffing model. While 2026 has been a transition year for the company, it is expected to see mid-teens-plus earnings growth in the future. Recent acquisitions, such as SteadyMD, have also shown promising growth and could be a potential white-label clinical back-end for other healthcare companies. Despite the current stock trading below its net cash value, the company is making progress in repositioning itself for future growth.
Bears say
DocGo is facing several challenges in its quest for profitability and sustainable growth. While the company's revenue has exceeded expectations in the most recent quarter, the increase was largely due to contributions from sunsetting migrant-related contracts, indicating a decline in organic non-migrant Mobile Health revenue. Additionally, the company's cost structure needs to be optimized to achieve its targeted adj-EBITDA profitability in 2026. The ongoing COVID-related uncertainty, with a potential decline in testing revenue in the future, also poses a risk for the company's financials. Despite the potential positive outcome from its exploration of strategic alternatives, it may take some time for investors to feel comfortable with the durability of DocGo's revenue stream, leading to a discounted valuation.
This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares